Вторичная организующаяся пневмония после перенесенной новой коронавирусной инфекции (обзор литературы)

Вторичная организующаяся пневмония после перенесенной новой коронавирусной инфекции (обзор литературы)

Автор: Гофман Л. С., Шендриков В. П., Мурлатова Е. Ю., Баздырев Е. Д.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 2 т.38, 2023 года.

Бесплатный доступ

Новая коронавирусная инфекция (COVID-19) помимо угрожающего жизни острого течения способна приводить к развитию симптомов, сохраняющихся длительное время. Клиническая, радиологическая и гистопатологическая картина посткоронавирусной пневмонии имеет общие признаки со вторичной организующейся пневмонией (ВОП). Считается, что данный вариант пневмонии служит одним из вариантов осложнений во время болезни, что не только коррелирует с тяжестью заболевания, но и приводит к более высоким показателям смертности пациентов. Необходимо отметить, что рентгенологические симптомы пневмонии наблюдаются даже у выздоровевших лиц примерно в 67% случаев. Несмотря на то, что у 25% лиц заболевание разрешается самостоятельно, а у большинства других легко поддается лечению, в 5-8% случаев может развиться фиброз, сопровождающийся симптомами дыхательной недостаточности. Специфического метода лечения ВОП на фоне новой коронавирусной инфекции в настоящее время не существует, к терапии первой линии относят применение глюкокортикостероидов (ГКС). Несмотря на эффективность ГКС, курс лечения составляет в среднем более полугода, при этом высока вероятность рецидива при прекращении терапии. Для определения оптимальных дозировок и длительности ГКС в терапии ВОП после перенесенного COVID-19 зарегистрированы клинические исследования, но единого мнения по данному вопросу нет, он остается открытым. В данном обзоре представлена информация об организующейся пневмонии, а также ВОП на фоне перенесенной новой коронавирусной инфекции, ее рентгенологической картине и вариантах лечения в рамках проводимых клинических исследований.

Еще

Новая коронавирусная инфекция, covid-19, постковидный синдром, интерстициальная пневмония, организующаяся пневмония, вторичная организующаяся пневмония, фиброз легких

Короткий адрес: https://sciup.org/149142850

IDR: 149142850   |   DOI: 10.29001/2073-8552-2023-38-2-64-71

Список литературы Вторичная организующаяся пневмония после перенесенной новой коронавирусной инфекции (обзор литературы)

  • Баздырев Е.Д. Коронавирусная инфекция - актуальная проблема XXI века. Комплексные проблемы сердечно-сосудистых заболеваний. 2020;9(2):6-16. https://doi.org/10.17802/2306-1278-2020-9-2-6-16.
  • Wu X., Liu X., Zhou Y., Yu H., Li R., Zhan Q. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir. Med. 2021;9(7):747-754. https://doi.org/10.1016/S2213-2600(21)00174-0.
  • Raoufi M., Kahkooei S., Haseli S., Robatjazi F., Bahri J., Khalili N. Organizing pneumonia-like pattern in COVID-19. Advances in Respiratory Medicine. 2021;89(6):565-569. https://doi.org/10.5603/ARM.a2021.0081.
  • Wang Y., Jin C., Wu C.C., Zhao H., Liang T., Liu Z. et al. Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings. PLoS One. 2020;15(11):e0240347. https://doi.org/10.1371/journal.pone.0240347.
  • Horii H., Kamada K., Nakakubo S., Yamashita Y., Nakamura J., Nasuhara Y. et al. Rapidly progressive organizing pneumonia associated with COVID-19. Respir. Med. Case Rep. 2020;31:101295. https://doi.org/10.1016/j.rmcr.2020.101295.
  • Bradley B., Branley H.M., Egan J.J., Greaves M.S., Hansell D.M., Harrison N.K. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(S5):v1-58. https://doi.org/10.1136/thx.2008.101691.
  • Kligerman S.J., Franks T.J., Galvin J.R. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics. 2013;33(7):1951-1975. https://doi.org/10.1148/rg.337130057.
  • Pathak V., Kuhn J.M., Durham C., Funkhouser W.K., Henke D.C. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. Ann. Am. Thorac. Soc. 2014;11(1):87-91. https://doi.org/10.1513/AnnalsATS.201308-261CR.
  • Cai M., Bonella F., Dai H., Sarria R., Guzman J., Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013;218(6):930-937. https://doi.org/10.1016/j.imbio.2012.10.014.
  • Poletti V., Cazzato S., Minicuci N., Zompatori M., Burzi M., Schiattone M.L. The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur. Respir. J. 1996;9(12):2513-2516. https://doi.org/10.1183/09031936.96.09122513.
  • Lee W.L., Downey G.P. Neutrophil activation and acute lung injury. Curr. Opin. Crit. Care. 2001;7(1):1-7. https://doi.org/10.1097/00075198-200102000-00001.
  • Ma Y., Zhang Y., Zhu L. Role of neutrophils in acute viral infection. Immun. Inflamm. Dis. 2021;9(4):1186-1196. https://doi.org/10.1002/iid3.500.
  • Radzikowska E., Roży A., Jaguś P., Wiatr E., Gawryluk D., Chorostowska-Wynimko J. et al. Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment. Adv. Exp. Med. Biol. 2016;911:77-85. https://doi.org/10.1007/5584_2016_223.
  • Baha A., Yıldırım F., Köktürk N., Galata Z., Akyürek N., Demirci N.Y. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiological and laboratory findings, treatment, and prognosis in 56 cases. Turk Thorac. J. 2018;19(4):201-208. https://doi.org/10.5152/TurkThoracJ.2018.18008.
  • Gudmundsson G., Sveinsson O., Isaksson H.J., Jonsson S., Frodadottir H., Aspelund T. Epidemiology of organising pneumonia in Iceland. Thorax. 2006;61(9):805-808. https://doi.org/10.1136/thx.2006.059469.
  • Allen J.N., Wewers M.D. HIV-associated bronchiolitis obliterans organizing pneumonia. Chest. 1989;96(1):197-198. https://doi.org/10.1378/chest.96.1.197.
  • Nuñez-Conde A., Marquez-Algaba E., Falcó V., Almirante B., Burgos J. Organizing pneumonia secondary to influenza infection: Two case reports and a literature review. Enferm. Infecc. Microbiol. Clin. (Engl. Ed.). 2020;38(3):123-126. (In Span.). https://doi.org/10.1016/j.eimc.2019.04.006.
  • Messina M., Scichilone N., Guddo F., Bellia V. Rapidly progressive organising pneumonia associated with cytomegalovirus infection in a patient with psoriasis. Monaldi Arch. Chest Dis. 2007;67(3):165-168. https://doi.org/10.4081/monaldi.2007.489.
  • Myall K.J., Mukherjee B., Castanheira A.M., Lam J.L., Benedetti G., Mak S.M. et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann. Am. Thorac. Soc. 2021;18(5):799-806. https://doi.org/10.1513/AnnalsATS.202008-1002OC.
  • Drakopanagiotakis F., Paschalaki K., Abu-Hijleh M., Aswad B., Karagianidis N., Kastanakis E. et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. Chest. 2011;139(4):893-900. https://doi.org/10.1378/chest.10-0883.
  • Choi K.J., Yoo E.H., Kim K.C., Kim E.J. Comparison of clinical features and prognosis in patients with cryptogenic and secondary organizing pneumonia. BMC Pulm. Med. 2021;21(1):336. https://doi.org/10.1186/s12890-021-01707-z.
  • Chandra D., Maini R., Hershberger D.M. Cryptogenic Organizing Pneumonia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
  • Greenberg-Wolff I., Konen E., Ben Dov I., Simansky D., Perelman M., Rozenman J. Cryptogenic organizing pneumonia: variety of radiologic findings. Isr. Med. Assoc. J. 2005;7(9):568-570.
  • Demedts M., Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur. Respir. J. 2002;19(5):794-796. https://doi.org/10.1183/09031936.02.00492002.
  • Wong K.T., Antonio G.E., Hui D.S., Ho C., Chan P.N., Ng W.H. et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004;28(6):790-795. https://doi.org/10.1097/00004728-200411000-00010.
  • Nishino M., Mathai S.K., Schoenfeld D., Digumarthy S.R., Kradin R.L. Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. Hum. Pathol. 2014;45(2):342-351. https://doi.org/10.1016/j.humpath.2013.09.010.
  • Onishi Y., Kawamura T., Higashino T., Mimura R., Tsukamoto H., Sasaki S. Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS One. 2021;16(4):e0249300. https://doi.org/10.1371/journal.pone.0249300.
  • Kobayashi T., Kitaichi M., Tachibana K., Kishimoto Y., Inoue Y., Kagawa T. et al. A Cryptogenic Case of Fulminant Fibrosing Organizing Pneumonia. Intern. Med. 2017;56(10):1185-1191. https://doi.org/10.2169/internalmedicine.56.7371.
  • Kim M., Cha S.I., Seo H., Shin K.M., Lim J.K., Kim H. et al. Predictors of Relapse in Patients with Organizing Pneumonia. Tuberc. Respir. Dis. (Seoul). 2015;78(3):190-195. https://doi.org/10.4046/trd.2015.78.3.190.
  • Ailing L., Ning X., Tao Q., Aijun L. Successful treatment of suspected organizing pneumonia in a patient without typical imaging and pathological characteristic: A case report. Respir. Med. Case Rep. 2017;22:246-250. https://doi.org/10.1016/j.rmcr.2017.09.007.
  • Barroso E., Hernandez L., Gil J., Garcia R., Aranda I., Romero S. Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting. Respiration. 2007;74(6):624-631. https://doi.org/10.1159/000103240.
  • American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165(2):277-304. https://doi.org/10.1164/ajrccm.165.2.ats01.
  • Ding Q.L., Lv D., Wang B.J., Zhang Q.L., Yu Y.M., Sun S.F. et al. Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review. Exp. Ther. Med. 2015;9(3):829-834. https://doi.org/10.3892/etm.2015.2183.
  • Radzikowska E., Wiatr E., Langfort R., Bestry I., Skoczylas A., Szczepulska-Wójcik E. et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. PLoS One. 2017;12(9):e0184739. https://doi.org/10.1371/journal.pone.0184739.
  • Cano E.J., Fonseca Fuentes X., Corsini Campioli C., O ҆Horo J.C., Abu Saleh O., Odeyemi Y. et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019-1040. https://doi.org/10.1016/j.chest.2020.10.054.
  • Epler G.R. Bronchiolitis obliterans organizing pneumonia, 25 years: a variety of causes, but what are the treatment options? Expert. Rev. Respir. Med. 2011;5(3):353-361. https://doi.org/10.1586/ers.11.19.
  • Lee J., Cha S.I., Park T.I., Park J.Y., Jung T.H., Kim C.H. Adjunctive effects of cyclosporine and macrolide in rapidly progressive cryptogenic organizing pneumonia with no prompt response to steroid. Intern. Med. 2011;50(5):475-479. https://doi.org/10.2169/internalmedicine.50.4237.
  • Koinuma D., Miki M., Ebina M., Tahara M., Hagiwara K., Kondo T. et al. Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid. Intern. Med. 2002;41(1):26-29. https://doi.org/10.2169/internalmedicine.41.26.
  • Kory P., Kanne J.P. SARS-CoV-2 organising pneumonia: “Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?” BMJ Open Respir. Res. 2020;7(1):e000724. https://doi.org/10.1136/bmjresp-2020-000724.
  • Vadász I., Husain-Syed F., Dorfmüller P., Roller F.C., Tello K., Hecker M. et al. Severe organising pneumonia following COVID-19. Thorax. 2021;76(2):201-204. https://doi.org/10.1136/thoraxjnl-2020-216088.
  • Kanne J.P., Little B.P., Chung J.H., Elicker B.M., Ketai L.H. Essentials for Radiologists on COVID-19: An Update-Radiology Scientific Expert Panel. Radiology. 2020;296(2):E113-E114. https://doi.org/10.1148/radiol.2020200527.
  • Fu F., Lou J., Xi D., Bai Y., Ma G., Zhao B. et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur. Radiol. 2020;30(10):5489-5498. https://doi.org/10.1007/s00330-020-06920-8.
  • Rocha A.S., Meireles M., Vilaça H., Guimarães T.C., Martins M.D., Santos L.R. et al. Outcomes of Covid-19 organizing pneumonia in critically ill patients. J. Infect. 2021;83(4):496-522. https://doi.org/10.1016/j.jinf.2021.06.025.
  • Antonio G.E., Wong K.T., Hui D.S., Wu A., Lee N., Yuen E.H. et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228(3):810-815. https://doi.org/10.1148/radiol.2283030726.
  • Cheung O.Y., Chan J.W., Ng C.K., Koo C.K. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology. 2004;45(2):119-124. https://doi.org/10.1111/j.1365-2559.2004.01926.x.
  • Kim I., Lee J.E., Kim K.H., Lee S., Lee K., Mok J.H. Successful treatment of suspected organizing pneumonia in a patient with Middle East respiratory syndrome coronavirus infection: a case report. J. Thorac. Dis. 2016;8(10):E1190-E1194. https://doi.org/10.21037/jtd.2016.09.26.
  • Elsoukkary S.S., Mostyka M., Dillard A., Berman D.R., Ma L.X., Chadburn A. et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56-68. https://doi.org/10.1159/000511325.
  • Borczuk A.C. Pulmonary pathology of COVID-19: a review of autopsy studies. Curr. Opin. Pulm. Med. 2021;27(3):184-192. https://doi.org/10.1097/MCP.0000000000000761.
  • Copin M.C., Parmentier E., Duburcq T., Poissy J., Mathieu D. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46(6):1124-1126. https://doi.org/10.1007/s00134-020-06057-8.
  • Buja L.M., Wolf D.A., Zhao B., Akkanti B., McDonald M., Lelenwa L. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 2020;48:107233. https://doi.org/10.1016/j.carpath.2020.107233.
  • Liu H., Li J., Chen M., Su J. Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: A case report. Medicine (Baltimore). 2019;98(34):e16839. https://doi.org/10.1097/MD.0000000000016839.
  • Roden A.C., Bois M.C., Johnson T.F., Aubry M.C., Alexander M.P., Hagen C.E. et al. The Spectrum of Histopathologic Findings in Lungs of Patients With Fatal Coronavirus Disease 2019 (COVID-19) Infection. Arch. Pathol. Lab. Med. 2021;145(1):11-21. https://doi.org/10.5858/arpa.2020-0491-SA.
  • Barbeta E., Benegas M., Sánchez M., Motos A., Ferrer M., Ceccato A. et al. Risk Factors and Clinical Impact of Fibrotic-Like Changes and the Organizing Pneumonia Pattern in Patients With COVID-19- and NonCOVID-19-Induced Acute Respiratory Distress Syndrome. Arch. Bronconeumol. 2022;58(2):183-187. https://doi.org/10.1016/j.arbres.2021.05.023.
  • Bae I.-G., Hong K.-W., Yang J.W., Moon K.l., Kim J.D., Ju S. et al. Persistent pneumonic consolidations due to secondary organizing pneumonia in a patient recovering from COVID19 pneumonia: A case report. Preprint (Version 1) available at Research Square; 2020. https://doi.org/10.21203/rs.3.rs-37580/v1.
  • Dhooria S. Comparison of the efficacy and safety of two corticosteroid regimens in the treatment of diffuse lung disease after coronavirus disease 2019 (COVID-19) pneumonia. ClinicalTrials.gov; 2022. URL: https://clinicaltrials.gov/ct2/show/NCT04657484 (27.01.2023).
  • Goel N., Goyal N., Nagaraja R., Kumar R. Systemic corticosteroids for management of “long-COVID”: an evaluation after 3 months of treatment. Monaldi Arch. Chest. Dis. 2021;92(2). https://doi.org/10.4081/monaldi.2021.1981.
  • Ayub I.I. Clarithromycin in Post Covid 19 parenchymal organizing pneumonia. Clinical Trials Registry-India; 2020. URL: https://covid-19.cochrane.org/studies/crs-16896926 (13.12.2022).
  • Tan H.X., Lim J.L., shih Khor I., Kew Y.Ch., Yik W.F., Chan Y.M. et al. P16-60: Post COVID-19 organizing pneumonia treated with mycophenolate mofetil. Respirology. 2021;26(S3):473-474. https://doi.org/10.1111/resp.14150_969.
  • Sugino K., Ono H., Haraguchi S., Igarashi S., Hebisawa A., Tsuboi E. Post-coronavirus disease 2019 organizing pneumonia confirmed pathologically by video-assisted thoracoscopic surgery. Respirol. Case Rep. 2021;9(12):e0871. https://doi.org/10.1002/rcr2.871.
Еще
Статья обзорная
SciUp 2024 © 2024 ©